Sino Biopharmaceutical (HKSE:01177) Debt-to-Equity : 0.41 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Debt-to-Equity?

Sino Biopharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$12,258 Mil. Sino Biopharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,502 Mil. Sino Biopharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$33,332 Mil. Sino Biopharmaceutical's debt to equity for the quarter that ended in Dec. 2023 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sino Biopharmaceutical's Debt-to-Equity or its related term are showing as below:

HKSE:01177' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.22 Med: 0.39 Max: 0.85
Current: 0.41

During the past 13 years, the highest Debt-to-Equity Ratio of Sino Biopharmaceutical was 0.85. The lowest was 0.22. And the median was 0.39.

HKSE:01177's Debt-to-Equity is ranked worse than
71.27% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:01177: 0.41

Sino Biopharmaceutical Debt-to-Equity Historical Data

The historical data trend for Sino Biopharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Debt-to-Equity Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.58

0.85

0.40

0.47

0.41

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.40	0.40	0.47	0.39	0.41

Competitive Comparison of Sino Biopharmaceutical's Debt-to-Equity

For the Biotechnology subindustry, Sino Biopharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Debt-to-Equity falls into.

Sino Biopharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sino Biopharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12258.448	+	1501.557)	/	33332.331
	=	0.41

Sino Biopharmaceutical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12258.448	+	1501.557)	/	33332.331
	=	0.41

Sino Biopharmaceutical (HKSE:01177) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sino Biopharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines